Total percutaneous correction of a tetralogy of Fallot variant with dominant pulmonary valve stenosis

E B Sideris, B Macuil, S Justiniano, P S Rao

Objective: To study the feasibility, efficacy, and safety of total percutaneous correction of a tetralogy of Fallot variant with dominant pulmonary valve stenosis.

Design: Percutaneous correction of a variant of tetralogy of Fallot with dominant pulmonary valve stenosis, on the basis that there are transcatheter methods for the correction of malalignment-type ventricular septal defect (VSD) (transcatheter patch) and valvar pulmonary stenosis (balloon valvoplasty).

Patients: Two patients with tetralogy of Fallot, 4 and 7 years old, were admitted for percutaneous correction. Their aortic saturations were 72% and 88%. Both had severe right ventricular outflow obstruction with dominant valvar pulmonary stenosis with total gradients of 120 and 70 mm Hg. Large malalignment subaortic VSDs, 14 and 16 mm in diameter, were present. The first patient had a previous percutaneous correction of a small atrial septal defect and an aortopulmonary collateral.

Interventions: Balloon valvoplasty was first performed, followed by balloon test occlusion of the VSD and double balloon patch occlusion. Forty eight hours after implantation the supporting balloons were extracted, releasing the patches.

Results: Both patients became acyanotic with oxygen saturations of 96%. There was mild residual infundibular stenosis with 40 and 30 mm Hg gradients. Both VSDs were effectively occluded with only trivial residual shunts. One patient developed mild haemolysis, which resolved spontaneously in a few days. Both patients were doing well at six and 12 months’ follow up visits.

Conclusions: Total percutaneous correction of the tetralogy of Fallot variants with dominant pulmonary valve stenosis is feasible and successful. Larger clinical trials are required to further assess effectiveness and safety.

Tetralogy of Fallot is the most common cyanotic heart disease in children. It consists of right ventricular outflow obstruction, malalignment-type subaortic ventricular septal defect (VSD), overriding aorta, and right ventricular hypertrophy. Total correction is performed by open heart surgery, where both the stenotic right ventricular outflow and the VSD are repaired. Palliation may be required for some patients before the total correction. The landmark for the beginning of both paediatric heart surgery and paediatric cardiology was the performance of a Blalock-Taussig shunt in a cyanotic patient with tetralogy of Fallot about 50 years ago. The evolution of treatment of tetralogy of Fallot from palliative to corrective surgery in infants and children was aided by an increasing role of transcatheter interventions. We present two cases of total percutaneous correction of a tetralogy of Fallot variant with dominant pulmonary stenosis, which in our opinion epitomises the progress made in the management of this disease.

PATIENTS AND METHODS

Two patients with known tetralogy of Fallot (7 and 4 years old) were admitted for possible percutaneous total correction. There were both cyanotic with their symptoms becoming worse over the years. Physical examination and ECG were consistent with tetralogy of Fallot. Chest radiography showed boot shaped hearts and right aortic arch.

Echocardiography revealed significant aortic overriding with non-restrictive subaortic VSDs (fig 1A). Both patients had dominant pulmonary valve stenosis and mild infundibular pulmonary stenosis. Pulmonary arteries were small, without significant branch stenosis. The first patient had undergone two additional transcatheter interventions seven months previously: a small atrial septal defect repaired by an Amplatzer device, and an aortopulmonary collateral occluded by a Gianturco coil.

Cardiac catheterisation and angiography confirmed the diagnosis of tetralogy of Fallot (fig 2A) with dominant severe pulmonary valvar stenosis and associated mild infundibular stenosis in both cases (table 1). There were large subaortic non-restrictive VSDs with equalisation of left ventricular and right ventricular peak systolic pressures. Aortic saturations were 72% and 88%. Informed consent was obtained from both parents after ethical committee approval, before the total percutaneous corrections were attempted. Pulmonary valvoplasty was performed first with angioplasty balloons (NuMED, Nicholville, New York, USA) 2 mm larger than the pulmonary annulus.

The VSD was easily crossed antegradely (from the right ventricle) and an arteriovenous wire connection was established. Test balloon occlusion was performed under fluoroscopy, echocardiography, and pressure monitoring with large sizing balloons (Sideris sizing balloon; NuMED). The occluding diameters of the defects were 14 mm and 16 mm and there was no change in the systemic pressure after 10 minute balloon occlusion of the defects. A 12 French long sheath (Cook, Bloomington, Indiana, USA) was introduced transvenously over the wire and its tip was positioned in the ascending aorta. A double balloon patch (Custom Medical Devices, Athens, Greece) was introduced over the wire and was released in the ascending aorta. The distal balloon/patch was inflated with a dilute contrast solution at a diameter 1 mm larger than the diameter found by balloon sizing and it was pulled back until the defect was occluded. The proximal balloon was inflated in the right ventricle with the same volume as the distal balloon (fig 1B). The arteriovenous wire was extracted. The whole procedure was performed under
fluoroscopy, echocardiography, and pressure monitoring. The double balloon catheter was immobilised in the groin and the patients were taken to the intensive care unit for overnight observation. Post-implantation chest radiographs and transthoracic echocardiograms were obtained. The patches were released under fluoroscopy and echocardiography in 48 hours. Both patients were followed up non-invasively after six and 12 months.

RESULTS

Pulmonary valvoplasty resulted in relief of the valvar obstruction with mild residual infundibular gradient (40 and 30 mm Hg). Full occlusion of the VSDs was noticed by echocardiography and left ventricular cineangiography (fig 1B), right after double balloon occlusion. The absence of significant left ventricular outflow gradient was confirmed during pullback of the angiographic catheter from the left ventricle to the aorta. Upon patch release both patients had effective occlusions (fig 1C) with a trivial residual shunt. The infundibular gradient has remained unchanged by Doppler.

Figure 1  Case 1. (A) Two dimensional echocardiogram on long axis view showing a large subaortic ventricular septal defect (VSD) and significant aortic overriding. AO, aorta; IVS, interventricular septum; LV, left ventricle; RV, right ventricle. (B) Long axial angiographic view showing transcatheter patch occlusion of the malalignment VSD. The distal balloon/patch (DBP) is inflated on the left side of the ventricular septum with the proximal balloon (PB) on the right side. The defect is fully occluded. (C) Five chamber apical echocardiographic view showing complete occlusion of the VSD after patch (P) release (48 hours).

Figure 2  Case 2. (A) Left anterior oblique projection of a left ventricular angiogram showing a large aorta, significant overriding, and large subaortic VSD. (B) Left ventricular angiogram on left anterior oblique projection after patch release (48 hours) showing effective occlusion of the VSD with a trivial residual shunt. r-VSD, residual ventricular septal defect.

Both patients were followed up non-invasively after six and 12 months.

www.heartjnl.com
The transcatheter patch is a polyurethane device delivered by balloon with a three dimensional structure, requiring a minimal rim to sit correctly. Furthermore, the absence of any wires diminishes the chances of aortic valve damage. The patch requires up to 48 hour balloon support until it is embedded in the septal wall. Fibrin is initially responsible for patch attachment with endothelialisation following very quickly. Accelerated patch release in less than 24 hours is also possible. The balloon/patch diameter is selected to be 1 mm larger than the balloon occluding diameter of the defect. The patch can be retrieved at any time before the release, since it is connected to a thread that is pulled after balloon withdrawal.

The transcatheter patch has been applied successfully in the occlusion of various heart defects, including subaortic rim and the malalignment. This VSD was successfully occluded by transcatheter patch in both patients.

The transcatheter patch is a polyurethane device delivered by balloon with a three dimensional structure, requiring a minimal rim to sit correctly. Furthermore, the absence of any wires diminishes the chances of aortic valve damage. The patch requires up to 48 hour balloon support until it is embedded in the septal wall. Fibrin is initially responsible for patch attachment with endothelialisation following very quickly. Accelerated patch release in less than 24 hours is also possible. The balloon/patch diameter is selected to be 1 mm larger than the balloon occluding diameter of the defect. The patch can be retrieved at any time before the release, since it is connected to a thread that is pulled after balloon withdrawal.

The transcatheter patch has been applied successfully in the occlusion of various heart defects, including subaortic rim and the malalignment. This VSD was successfully occluded by transcatheter patch in both patients.

The diagnostic labelling of this case may be a subject of debate for the pathologist. Our opinion is that we had a cyanotic tetralogy of Fallot variant with dominant pulmonary valvar stenosis in feasible and appeared effective and safe in the two described cases. Larger clinical trials are justified.

**REFERENCES**

Total percutaneous correction of a tetralogy of Fallot variant with dominant pulmonary valve stenosis

E B Sideris, B Macuil, S Justiniano and P S Rao

*Heart* 2005 91: 345-347
doi: 10.1136/hrt.2003.031682

Updated information and services can be found at:
http://heart.bmj.com/content/91/3/345

These include:

**References**
This article cites 10 articles, 1 of which you can access for free at:
http://heart.bmj.com/content/91/3/345#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8839)
- Right sided valvular heart disease (125)
- Congenital heart disease (761)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/